- Report
- January 2026
- 198 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- June 2026
- 376 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- January 2026
- 180 Pages
Global
From €4090EUR$4,500USD£3,527GBP
- Report
- March 2026
- 149 Pages
Global
From €3635EUR$3,999USD£3,135GBP
- Report
- December 2025
- 150 Pages
Global
From €4408EUR$4,850USD£3,802GBP
- Report
- February 2026
- 144 Pages
Global
From €3590EUR$3,950USD£3,096GBP
- Report
- June 2026
- 193 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- January 2026
- 184 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- August 2025
- 186 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- August 2025
- 182 Pages
Global
From €3222EUR$3,545USD£2,779GBP
€3580EUR$3,939USD£3,088GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,519GBP
- Report
- June 2026
- 189 Pages
Global
From €5317EUR$5,850USD£4,586GBP
- Report
- January 2026
- 281 Pages
Global
From €2272EUR$2,500USD£1,960GBP
- Report
- February 2026
- 196 Pages
Global
From €4408EUR$4,850USD£3,802GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more